Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 21, 2016; 22(3): 1260-1278
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1260
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1260
Parameter | Healthy subjects | Patients with cirrhosis | ||||
Child A | Child C | |||||
Placebo | Fluvoxamine | Placebo | Fluvoxamine | Placebo | Fluvoxamine | |
CL lidocaine | 12.10 ± 3.38 | 4.85 ± 4.85c | 9.83 ± 3.99 | 5.06 ± 1.75c | 4.21 ± 1.56e | 3.65 ± 0.99 |
Inhibition (%) | 60 (53-77) | 44 (28-59) | 9 (0-19)e | |||
Fluvoxamine AUC0-14 | 866 ± 331 | 1277 ± 381 | 2316 ± 790d | |||
CL theophylline | 0.825 ± 0.201 | 0.302 ± 0.080c | 0.660 ± 0.231 | 0.310 ± 0.104a | 0.296 ± 0.124d | 0.251 ± 0.151 |
Inhibition (%) | 64 (59-69) | 55 (46-66) | 14 (0-29) | |||
CLf 3-MX | 0.192 ± 0.069 | 0.008 ± 0.007c | 0.124 ± 0.051 | 0.011 ± 0.017c | 0.037 ± 0.012d | 0.023 ± 0.013a |
Inhibition (%) | 97 (93-100) | 92 (84-100) | 38 (18-58) | |||
CLf 1-MU | 0.220 ± 0.089 | 0.021 ± 0.019c | 0.178 ± 0.072 | 0.026 ± 0.018c | 0.066 ± 0.025d | 0.039 ± 0.019a |
Inhibition (%) | 93 (89-98) | 83 (73-93) | 36 (15-57) | |||
CLf 1,3-DMU | 0.290 ± 0.070 | 0.136 ± 0.024c | 0.222 ± 0.058 | 0.138 ± 0.026c | 0.087 ± 0.040d | 0.079 ± 0.037 |
Inhibition (%) | 58 (49-67) | 43 (29-58) | 7 (0-22) | |||
CLR theophylline | 0.123 ± 0.033 | 0.136 ± 0.030 | 0.136 ± 0.050 | 0.135 ± 0.043 | 0.106 ± 0.047 | 0.110 ± 0.062 |
Inhibition (%) | - | - | - | |||
Fluvoxamine Css | 75 ± 26 | 95 ± 40 | 130 ± 26b |
Parameter | Healthy subjects | Patients with cirrhosis | ||||
Child A | Child C | |||||
Placebo | Erythromycin | Placebo | Erythromycin | Placebo | Erythromycin | |
CL quinine | 1.775 ± 0.310 | 1.161 ± 0.309a | 1.504 ± 0.362 | 1.040 ± 0.303a | 1.281 ± 0.394b | 1.401 ± 0.534 |
Inhibition (%) | 33 (27-38) | 30 (26-34) | -7 (-16-2)f | |||
CLf 3-hydroxiquinine | 0.174 ± 0.051 | 0.059 ± 0.017c | 0.140 ± 0.077 | 0.056 ± 0.032c | 0.085 ± 0.028d | 0.037 ± 0.023c |
Inhibition (%) | 65 (61-70) | 61 (56-67) | 59 (46-72) | |||
Unbound quinine (%) | 6.7 ± 0.8 | 9.4 ± 1.0c | 7.1 ± 1.6 | 10.3 ± 2.8c | 11.9 ± 3.7f | 19.9 ± 5.5cf |
Increase (%) | 41 (28-55) | 45 (33-55) | 76 (42-111)b | |||
CLu quinine | 26.81 ± 11.49 | 12.30 ± 3.16c | 21.18 ± 8.45 | 10.10 ± 3.88c | 10.95 ± 2.19f | 7.24 ± 2.77bc |
Inhibition (%) | 51 (44-59) | 50 (45-55) | 35 (21-48)b | |||
CLuf 3-hydroxiquinine | 2.63 ± 0.88 | 0.64 ± 0.20c | 1.97 ± 1.09 | 0.55 ± 0.31c | 7.01 ± 3.33f | 4.06 ± 2.58ad |
Inhibition (%) | 75 (70-80) | 73 (70-77) | 74 (64-84) | |||
Erythromycin Css | 1.33 ± 0.25 | 1.18 ± 0.44 | 1.85 ± 1.00 |
- Citation: Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol 2016; 22(3): 1260-1278
- URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1260.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1260